Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio.

IF 3.5 3区 医学 Q2 CHEMISTRY, MULTIDISCIPLINARY
Pharmaceutical Research Pub Date : 2025-04-01 Epub Date: 2025-04-04 DOI:10.1007/s11095-025-03854-y
Yuki Tarumi, Yuji Higashiguchi, Kiyohiko Sugano
{"title":"Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio.","authors":"Yuki Tarumi, Yuji Higashiguchi, Kiyohiko Sugano","doi":"10.1007/s11095-025-03854-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to investigate the correlation between the dissolution profiles of salt-form drugs in biorelevant bicarbonate buffer and oral drug absorption.</p><p><strong>Methods: </strong>Ciprofloxacin HCl (CPFX HCl), garenoxacin mesylate (GRNX MS), tosufloxacin tosylate (TFLX TS), levofloxacin free-form (LVFX FF), and sitafloxacin free-form (STFX FF) were employed as model drugs. Bicarbonate buffer fasted state simulated intestinal fluid (BCB-FaSSIF) was used as a biorelevant dissolution medium (pH 6.5, BCB 10 mM (floating lid method), taurocholic acid (3 mM) and lecithin (0.75 mM)). The fraction of a dose absorbed in humans (Fa) was predicted by a simple theoretical framework for oral drug absorption using equilibrium solubility at pH 6.5 (S<sub>eq,pH6.5</sub>) or average dissolved drug concentration in the dissolution tests (C<sub>dissolv,AV</sub>).</p><p><strong>Results: </strong>Fa was adequately predicted using S<sub>eq,pH6.5</sub> for LVFX FF and STFX FF, however, underpredicted for CPFX HCl (tenfold), GRNX MS (twofold), and TFLX TS (sevenfold). When compendial Dose/FV was used for the dissolution test of CPFX HCl, bulk pH (pH<sub>bulk</sub>) remained unchanged and C<sub>dissolv,AV</sub> ≈ S<sub>eq,pH6.5</sub>, resulting in a tenfold underprediction of Fa. Using clinical Dose/FV, pH<sub>bulk</sub> was decreased, C<sub>dissolv,AV</sub> was increased, resulting in adequate Fa prediction. Similarly, for GRNX MS and TFLX TS, Fa predictability was improved using C<sub>dissolv,AV</sub> at clinical Dose/FV. In these conditions, C<sub>dissolv,AV</sub> > S<sub>eq,pH6.5</sub> due to decreased pH<sub>bulk</sub> below the first pK<sub>a</sub> of the drugs.</p><p><strong>Conclusion: </strong>The use of clinical Dose/FV was important for improving the correlation between the biorelevant dissolution profiles and Fa for salt-form drugs.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"623-637"},"PeriodicalIF":3.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055928/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11095-025-03854-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The purpose of this study was to investigate the correlation between the dissolution profiles of salt-form drugs in biorelevant bicarbonate buffer and oral drug absorption.

Methods: Ciprofloxacin HCl (CPFX HCl), garenoxacin mesylate (GRNX MS), tosufloxacin tosylate (TFLX TS), levofloxacin free-form (LVFX FF), and sitafloxacin free-form (STFX FF) were employed as model drugs. Bicarbonate buffer fasted state simulated intestinal fluid (BCB-FaSSIF) was used as a biorelevant dissolution medium (pH 6.5, BCB 10 mM (floating lid method), taurocholic acid (3 mM) and lecithin (0.75 mM)). The fraction of a dose absorbed in humans (Fa) was predicted by a simple theoretical framework for oral drug absorption using equilibrium solubility at pH 6.5 (Seq,pH6.5) or average dissolved drug concentration in the dissolution tests (Cdissolv,AV).

Results: Fa was adequately predicted using Seq,pH6.5 for LVFX FF and STFX FF, however, underpredicted for CPFX HCl (tenfold), GRNX MS (twofold), and TFLX TS (sevenfold). When compendial Dose/FV was used for the dissolution test of CPFX HCl, bulk pH (pHbulk) remained unchanged and Cdissolv,AV ≈ Seq,pH6.5, resulting in a tenfold underprediction of Fa. Using clinical Dose/FV, pHbulk was decreased, Cdissolv,AV was increased, resulting in adequate Fa prediction. Similarly, for GRNX MS and TFLX TS, Fa predictability was improved using Cdissolv,AV at clinical Dose/FV. In these conditions, Cdissolv,AV > Seq,pH6.5 due to decreased pHbulk below the first pKa of the drugs.

Conclusion: The use of clinical Dose/FV was important for improving the correlation between the biorelevant dissolution profiles and Fa for salt-form drugs.

盐型药物在生物相关碳酸氢盐缓冲液中的溶出曲线与口服药物吸收的相关性:剂量/液体积比的重要性
目的:研究盐型药物在生物相关碳酸氢盐缓冲液中的溶出度与口服药物吸收的关系。方法:以盐酸环丙沙星(CPFX HCl)、甲磺酸加硝沙星(GRNX MS)、tosuflo沙星tosysyate (TFLX TS)、游离左氧氟沙星(LVFX FF)、游离西他沙星(STFX FF)为模型药物。采用碳酸氢盐缓冲禁食状态模拟肠液(BCB- fassif)作为生物相关溶出介质(pH 6.5, BCB 10 mM(浮盖法),牛磺胆酸(3 mM)和卵磷脂(0.75 mM))。通过口服药物吸收的简单理论框架,使用pH6.5 (Seq,pH6.5)的平衡溶解度或溶出试验中的平均溶解药物浓度(Cdissolv,AV)来预测人体吸收剂量的分数(Fa)。结果:使用Seq可以充分预测Fa, LVFX FF和STFX FF的pH6.5低于CPFX HCl(10倍),GRNX MS(2倍)和TFLX TS(7倍)。使用药典剂量/FV进行CPFX HCl溶出试验时,体pH (pHbulk)保持不变,Cdissolv,AV≈Seq,pH6.5,导致Fa低估10倍。使用临床剂量/FV, pHbulk降低,Cdissolv增加,AV增加,可以充分预测Fa。同样,对于GRNX MS和TFLX TS,使用Cdissolv,AV在临床剂量/FV下可提高Fa的可预测性。在这些条件下,由于pHbulk低于药物的第一个pKa, Cdissolv,AV > Seq,pH6.5。结论:临床剂量/FV的使用对改善盐型药物生物相关溶出谱与Fa的相关性具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutical Research
Pharmaceutical Research 医学-化学综合
CiteScore
6.60
自引率
5.40%
发文量
276
审稿时长
3.4 months
期刊介绍: Pharmaceutical Research, an official journal of the American Association of Pharmaceutical Scientists, is committed to publishing novel research that is mechanism-based, hypothesis-driven and addresses significant issues in drug discovery, development and regulation. Current areas of interest include, but are not limited to: -(pre)formulation engineering and processing- computational biopharmaceutics- drug delivery and targeting- molecular biopharmaceutics and drug disposition (including cellular and molecular pharmacology)- pharmacokinetics, pharmacodynamics and pharmacogenetics. Research may involve nonclinical and clinical studies, and utilize both in vitro and in vivo approaches. Studies on small drug molecules, pharmaceutical solid materials (including biomaterials, polymers and nanoparticles) biotechnology products (including genes, peptides, proteins and vaccines), and genetically engineered cells are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信